Search Within

Gopakumar Vasudeva Iyer

  1. "2024"
Formats
  1. Meeting Abstract (34)
  2. Journal Article (6)
  3. Review (1)
Groups
  1. Department of Medicine (41)
  2. Genitourinary Oncology Service (41)
  3. Solid Tumor Oncology Division (41)
  4. Graduate Medical Education (16)
  5. Department of Pathology and Laboratory Medicine (15)
  6. Human Oncology and Pathogenesis Program (14)

More Groups

People
  1. Hikmat Al-Ahmadie (15)
  2. Jonathan Rosenberg (14)
  3. David Solit (13)
  4. Eugene Pietzak (13)
  5. Dean Bajorin (10)
  6. Min Yuen Teo (9)

More People

Years
  1. 2024 (41)
Publications
  1. Journal of Clinical Oncology (18)
  2. European Journal of Cancer (5)
  3. Urologic Oncology: Seminars and Original Investigations (5)
  4. Annals of Oncology (2)
  5. European Urology (2)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. Elsevier Inc. (11)
  3. Oxford University Press (3)
  4. Elsevier Science, Inc. (2)
  5. Nature Publishing Group (2)
  6. Elsevier BV (1)

More Publishers

Results (41)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Spatial profiling of urothelial carcinoma with aberrant histology identified significant intratumoral molecular and immune heterogeneity with clinical implications
    Meeting Abstract

    Kuo, F.; Basar, M.; Koll, F.; Chen, J. F.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Gopalan, A.; Fine, S.; Tickoo, S.; more...
    Laboratory Investigation (2024)

    Fulltext@MSK | Save
  • Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)
    Meeting Abstract

    Galsky, M. D.; Grande, E.; Necchi, A.; Koontz, M. Z.; Iyer, G.; Campbell, M. T.; Drakaki, A.; Loriot, Y.; Sokolowski, K. M.; Zhang, W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRECISION 1: A phase 2, multicenter, open-label basket trial of <i>nab</i>-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
    Meeting Abstract

    Iyer, G.; Kwiatkowski, D. J.; Ding, L.; Schmid, A. N.; Navarro, W. H.; Ahnert, J. R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma
    Meeting Abstract

    Iyer, G.; Gao, X.; Rasco, D. W.; Milowsky, M. I.; Garmezy, B.; Rivera, I. I. R.; Tepper, J.; Moles, M. A.; Gjini, E.; Bowden, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
    Meeting Abstract

    Van der Heijden, M. S.; Powles, T.; Gupta, S.; Bedke, J.; Kikuchi, E.; De Wit, R.; Galsky, M. D.; Duran, I.; Necchi, A.; Retz, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
    Meeting Abstract

    Iyer, G.; Palma, N. A.; Navarro, W. H.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save